More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$115.92B
EPS
3.76
P/E ratio
10.8
Price to sales
1.8
Dividend yield
5.089%
Beta
0.302286
Previous close
$48.39
Today's open
$47.54
Day's range
$47.50 - $47.96
52 week range
$39.07 - $52.67
show more
CEO
Belén Garijo
Employees
74846
Headquarters
Paris,
Exchange
Nasdaq Global Select
Shares outstanding
2.44B
Issue type
American Depository Receipt
Healthcare
Pharmaceuticals
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London.
MarketBeat • 20 hours ago

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Market Watch • Nov 12, 2026

69 Dividend Champions Ranked By Quality Scores (November 2026)
I present 69 Dividend Champions with Dividend Safety scores of 8+ and rank them using my 9F Quality Scores system. Twenty-two featured Dividend Champions are undervalued, while 21 are overvalued. Forty-nine have quality scores ≥ 7.0, indicating high quality. Top candidates by style: BRO and BMI for growth; BRO, BMI, and RGLD (below $262) for total return; CTBI for income; CAT for past performance.
Seeking Alpha • Nov 7, 2026

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 3.7%, we present two other groups of five DGI stocks, each with moderate to high yields of up to 8%.
Seeking Alpha • Nov 7, 2026

Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
Shares of Nurix Therapeutics crashed Wednesday after Sanofi unexpectedly scrapped an experimental eczema drug that two were codeveloping.
Investors Business Daily • Nov 4, 2026

Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It
Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increased 16.2% year over year, up 14.3% in constant currency.
Benzinga • Oct 30, 2026

Sanofi Q3 Earnings Call Highlights
Sanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. The company also raised its full-year sales and business EPS outlook while outlining a strategy focused on immunology, rare diseases and vaccines.
MarketBeat • Oct 30, 2026

Sanofi CEO Sets Sights on Deals to Drive Turnaround
The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.
WSJ • Oct 30, 2026

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.
Zacks Investment Research • Oct 30, 2026

Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.
24/7 Wall Street • Oct 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Sanofi commission-free¹. Build wealth for the long term using automated trading and transfers.